POSTED: 04:53 p.m. HST, Nov 01, 2011
Aiea-based Hawaii Biotech said it has acquired several licenses for technology that it had developed but lost when part of the company was sold last year.
Hawaii Biotech acquired an exclusive license for tick-borne encephalitis and malaria virus vaccine technology and a non-exclusive license for “recombinant protein expression” technology, the company announced today. The licenses were acquired from Merck, which obtained them when it bought certain assets of Hawaii Biotech in 2010.
“These licenses will enable HBI to proceed with the development of vaccines for TBE, malaria and potentially other subunit vaccines for important emerging and re-emerging infectious diseases and represent a significant milestone for Hawaii Biotech,” said Elliot Parks, Hawaii Biotech chief executive officer.